Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.440 +0.070 (+5.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,973,491
Open 1.340
Bid (Size) 1.400 (1)
Ask (Size) 1.450 (35)
Prev. Close 1.370
Today's Range 1.305 - 1.465
52wk Range 1.300 - 4.300
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
Via Benzinga

Performance

YTD
-34.5%
-34.5%
1 Month
-20.0%
-20.0%
3 Month
-34.5%
-34.5%
6 Month
-43.1%
-43.1%
1 Year
-64.6%
-64.6%

More News

Read More
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in March Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
Via Stocktwits
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Tuesday's session: gap up and gap down stocks
Via Chartmill
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Friday's session: top gainers and losers
Via Chartmill
What's going on in today's session
Via Chartmill
Friday's session: gap up and gap down stocks
Via Chartmill
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in February Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in December Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.440
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 04/02/25 04:00 PM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 204.74M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 205M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.